132results about How to "Enhance cellular immunity" patented technology

The present invention provides antigen delivery compositions and methods of using same to prevent or to treat cancers and other infectious diseases. More particularly, the present invention provides a lipid-protamine-DNA (LPD) vaccine delivery system and methods of using such LPD vaccine delivery system for the prevention and treatment of cancer and other infectious diseases.

The invention provides a porcine epidemic diarrhea virus inactivated vaccine. The porcine epidemic diarrhea virus inactivated vaccine contains the inactivated porcine epidemic diarrhea virus and an adjuvant, wherein the adjuvant is prepared from the following components in percentage by weight: 5% of squalane, 1% of oleic acid, 1% of Tween 80, 92% of 0.005M sodium citrate buffer solution, and 1% of beta-glucan, the porcine epidemic diarrhea virus is prepared by inactivating the porcine epidemic diarrhea virus strain PEDV-KB2013-4, is assigned with the microbial accession number of CGMCC No.12663, has the classification name of Porcine Epidemic Diarrhea Virus (PEDV), and is preserved in the China General Microbiological Culture Collection Center (CGMCC) on Aug 23, 2016, and the preservation address is the Institute of Microbiology of Chinese Academy of Sciences located in 3, Courtyard 1, West Beichen Road, Chaoyang District, Beijing.

Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-IBB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.

The present invention provides a cancer vaccine tape preparation for inducing cellular immunity, comprising:

• • a support,
  • an adhesive layer comprising an adhesive disposed on one side of the support, wherein the adhesive layer carries a combination of:
  • (i) a WT1 peptide and/or a modified WT1 peptide; and
  • (ii) a first cellular immunity induction promoter. The tape preparation can provides high efficacy.

The invention discloses a Newcastle disease-H9 subtype avian influenza bivalent dual-adjuvant inactivated vaccine and a preparation method thereof. The bivalent vaccine consists of a concentrated and inactivated ND and AI (H9) venom, levamisole hydrochloride and an oil adjuvant, wherein every milliliter of inactivated vaccine contains 0.5-16 mg of levamisole hydrochloride immunopotentiator. When the synergic ND-AI (H9) bivalent dual-adjuvant inactivated vaccine prepared with the method is applied to immunized chicken, the humoral immunity and cell immune levels of table poultry and laying hens can be raised effectively, the growth is promoted, and rate of live weight growth is increased. The bivalent dual-adjuvant inactivated vaccine has an immune effect which is remarkably superior to that of the conventional chicken ND-AI bivalent oil emulsion inactivated vaccine, and can be used for effectively protecting chicken flocks from being intruded by the ND virus and AI (H9) virus and preventing the Newcastle disease and H9 subtype avian influenza at the immune period.

The invention provides a heat-resistant freeze-drying protective agent applied to animal freeze-dried live vaccine. The heat-resistant freeze-drying protective agent comprises 1%-3% of glutin, 1%-8% of lactose and the like, wherein, all substances are dry components, and distilled water takes all the rest percentage. The invention also provides a method for preparing the protective agent. ND live vaccine prepared by the protective agent of the invention can be conserved for more than 24 months at the temperature of 2 DEG C to 8 DEG C. Immunity test shows that the average antibody level of immunized chicken is 1 to 2 titers higher than the average antibody level of tested chicken immunized by the ND live vaccine which is freeze-dried by ordinary protective agent, and the antibody level is uniform. Therefore, the freeze-drying protective agent can be widely applied to the production and conservation of various animal live vaccines and has wide application prospect.

The invention provides a vaccine composition for transdermal or transmucosal administration for inducing cellular immunity, comprising (i) an antigen; and (ii) a pharmacologically acceptable acid or a pharmacologically acceptable salt thereof as a first cellular immunity induction promoter.

The safe mixed feed for aquatic animal includes base feed and added compound microecological preparation in the amount of 0.02-0.05 wt% of the base feed. The compound microecological preparation is mixture of fissiparous vibrio and bacillus in the weight ration of 1 to 1-2. The safe mixed feed can raise the immunity of aquatic animal, reduce diseases and raise survival rate obviously.

A detoxicating synergistic Chinese medicine for radiotherapy or chemicotherapy is prepared from astragalus root, wolfberry fruit and ganoderma. Its advantage is high curative effect.

The invention discloses a livestock compound medicine with anti-virus and immune regulation functions. The livestock compound medicine is prepared from astragalus root, codonopsis pilosula, angelica, hedyotis diffusa, honeysuckle, radix bupleuri, liquorice and Isoprinosine. The livestock compound medicine has the functions of invigorating spleen-stomach and replenishing qi, replenishing blood, invigorating the circulation of blood, strengthening spleen and tonifying lung, clearing away heat and toxic materials, protecting liver, anti-inflammatory and reinforcing the organism immunity and has excellent treatment effect on various immune suppression diseases of livestock. The livestock compound medicine can improve the organism immunity of livestock, reinforce the cell immunity of livestock, promote the antibody generation, eliminate the organism immunity inhibition and effectively prevent and treat the livestock virosis. After use, the livestock compound medicine can promote the lymphocyte proliferation, increase the phagocytotic ability of phagocyte, reinforce the organism immunity of livestock, eliminate the organism immunity inhibition and greatly reduce the injury of immunosuppressive diseases to the livestock organism. The livestock compound medicine has no medicine residue, meets the safety and health requirements of livestock foods and is convenient to use; the livestock compound medicine can be taken together with drinking water or can be mixed with feed without affecting the export of such animal products as livestock products.

The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one therapeutic factor. The disclosure also provides methods of reducing an immune suppressor cell population in a mammal, methods of augmenting an immune response in a mammal, and methods of treating a disease in a mammal utilizing the vaccine compositions.

The invention discloses a fat emulsifier for feed use. The fat emulsifier contains the following components, by weight, 200-300 parts of granulesten, 10-50 parts of sucrose ester, 10-50 parts of monoglyceride, 10-20 parts of taurine and 580-770 parts of an excipient. A preparation method of the fat emulsifier contains the following steps: mixing granulesten and monoglyceride in proportion, heating to 60 DEG C, spraying the mixture into the excipient, uniformly mixing and drying to prepare a mixture; adding components excluding granulesten, monoglyceride and the excipient into the mixture; placing the mixture obtained from the step (3) into an agitator, stirring for 1-2 hours, putting the mixture into a pulverizer for primary crushing, taking out the crushed mixture and putting the crushed mixture into a ultrafine grinder for secondary crushing so as to obtain fine particles, sieving through a 100-mesh sieve, sealing and packaging so as to obtain the fat emulsifier for feed use. The fat emulsifier can emulsify most mixed lipid and has a large emulsification range. Meanwhile, the emulsifier can be added in the most economic mode, thus remarkably reducing breeding cost.

The present invention relates to a preparation method of polyporus polysaccharide sulfate. Said method includes the following steps: (1). preparing esterification reagent; (2). selecting and using polyporus polysaccharide powder and anhydrous methanamide or dimethyl methanamide according to mass ratio of 0.4-2.0:36-48, making the polyporus polysaccharide powder be suspended in anhydrous methanamide or dimethyl methanamide to obtain polyporus polysaccharide suspension; (3). making esterification reaction; (4). precipitation; (5). purifications and (6). secondary precipitation. Besides, said invention also provides the concrete requirement of every step.

This invention is in the field of identifying patients having rheumatic heart disease (RHD) associated with Streptococcus pyogenes (Group A Streptococcus; GAS) infection and identifying patients at risk of developing RHD associated with GAS infection. The invention also provides methods and compositions for preventing and treating RHD associated with GAS infection.

The invention discloses glycyrrhiza polysaccharide granules and a preparation method thereof; a tissue culture method is adopted to produce glycyrrhiza polysaccharide, and the glycyrrhiza polysaccharide granules can be prepared by the glycyrrhiza polysaccharide and other excipients. The glycyrrhiza polysaccharide granules comprise the components by parts: 100-150 parts of glycyrrhiza polysaccharide, 100-300 parts of sustained-release material, 100-200 parts of filler and 5-10 parts of adhesive. The glycyrrhiza polysaccharide is produced by being cultured by a fermentation tank; the developed glycyrrhiza polysaccharide granules are convenient to use and can be directly taken or taken with water; the produced glycyrrhiza polysaccharide has obvious immune dispensing activity and is capable of activating macrophage and tuberculosis (TB) lymphocyte, so that humoral immunity and cellular immunity can be enhanced, and the aims of improving the general immunity function and more effectively inhibiting tumours and acquired immunodeficiency syndrome (AIDS) can be achieved; furthermore, products developed by the polysaccharide have obvious health care function so as to have excellent develop space.

The instant invention comprises a process for selecting and manufacturing antibodies useful for therapeutic, prophylactic, diagnostic or research purposes using epitope peptide mixtures synthesized by the solid phase synthesis, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting antibodies are related to but distinct from antibodies that bind to the known epitope.

The present invention relates to filovirus VLPs and their use in activating innate immunity, specifically natural killer cells, and in enhancing an immune response to an antigen in an animal.